Carvalho Diego Z, Kolla Bhanu Prakash, McCarter Stuart J, St Louis Erik K, Machulda Mary M, Przybelski Scott A, Fought Angela J, Lowe Val J, Somers Virend K, Boeve Bradley F, Petersen Ronald C, Jack Clifford R, Graff-Radford Jonathan, Varga Andrew William, Vemuri Prashanthi
Center for Sleep Medicine, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Rochester, MN.
Department of Neurology, Mayo Clinic, Rochester, MN.
Neurology. 2025 Oct 7;105(7):e214155. doi: 10.1212/WNL.0000000000214155. Epub 2025 Sep 10.
The relationship between insomnia and cognitive decline is poorly understood. We investigated associations between chronic insomnia, longitudinal cognitive outcomes, and brain health in older adults.
From the population-based Mayo Clinic Study of Aging, we identified cognitively unimpaired older adults with or without a diagnosis of chronic insomnia who underwent annual neuropsychological assessments (z-scored global cognitive scores and cognitive status) and had quantified serial imaging outcomes (amyloid-PET burden [centiloid] and white matter hyperintensities from MRI [WMH, % of intracranial volume]). We used mixed-effects models to examine associations between baseline insomnia (independently or with interaction with self-reported changes in habitual sleep duration) and longitudinal cognitive z-scores, log-transformed WMH, and amyloid-PET levels while adjusting for multiple confounders, including sleep apnea diagnosis. The risk of incident cognitive impairment (CI) was estimated using the Cox proportional hazards model.
We included 2,750 participants (mean 70.3 ± 9.7 years old, 49.2% female) in global cognition models and 2,814 in Cox models with median follow-up of 5.6 years. A total of 1,027 and 561 participants were included in WMH and amyloid-PET models, respectively. Insomnia was associated with a 0.011 per year (95% CI -0.020 to -0.001, -interaction = 0.028) faster decline in global cognitive scores and 40% increased risk of CI (hazard ratio [HR] 1.4, 95% CI 1.07-1.85, = 0.015). Insomnia with reduced sleep was associated with baseline cognitive performance (β = -0.211, 95% CI -0.376 to -0.046, -interaction = 0.012), WMH (β = 0.147, 95% CI 0.044-0.249, -interaction = 0.005), and amyloid-PET (β = 10.5, 95% CI 0.5-20.6, -interaction = 0.039) burden. Insomnia participants sleeping more than usual (potentially indicating remission of symptoms) had lower baseline WMH burden (β = -0.142, 95% CI -0.268 to -0.016, -interaction = 0.028). Insomnia was not associated with the rate of WMH or amyloid accumulation over time. In participants with insomnia, hypnotic use was not associated with cognitive scores (β = 0.016, 95% CI -0.201 to 0.233, = 0.888) or incident CI (HR 0.94, 95% CI 0.5-1.6, = 0.832).
We found an association between insomnia, cognitive decline, and increased risk for CI. Insomnia with reduced sleep was associated with worse cognitive performance and poorer brain health (WMH and amyloid burden) at baseline. Sleeping more than usual was associated with lower WMH burden.
失眠与认知衰退之间的关系尚不清楚。我们研究了老年人慢性失眠、纵向认知结果和脑健康之间的关联。
在基于人群的梅奥诊所衰老研究中,我们确定了认知功能未受损的老年人,他们有或没有慢性失眠诊断,接受年度神经心理学评估(标准化全球认知评分和认知状态),并进行了系列成像结果量化(淀粉样蛋白PET负荷[百分位数]和MRI的白质高信号[WMH,颅内体积百分比])。我们使用混合效应模型,在调整包括睡眠呼吸暂停诊断在内的多个混杂因素的同时,研究基线失眠(独立或与自我报告的习惯性睡眠时间变化相互作用)与纵向认知标准化评分、对数转换后的WMH和淀粉样蛋白PET水平之间的关联。使用Cox比例风险模型估计发生认知障碍(CI)的风险。
我们在全球认知模型中纳入了2750名参与者(平均年龄70.3±9.7岁,49.2%为女性),在Cox模型中纳入了2814名参与者,中位随访时间为5.6年。WMH模型和淀粉样蛋白PET模型分别纳入了1027名和561名参与者。失眠与全球认知评分每年下降0.011(95%CI -0.020至-0.001,交互作用=0.028)以及CI风险增加40%(风险比[HR]1.4,95%CI 1.07-1.85,P=0.015)相关。睡眠减少的失眠与基线认知表现(β=-0.211,95%CI -0.376至-0.046,交互作用=0.012)、WMH(β=0.147,95%CI 0.044-0.249,交互作用=0.005)和淀粉样蛋白PET(β=10.5,95%CI 0.5-20.6,交互作用=0.039)负荷相关。睡眠时间比平时多的失眠参与者(可能表明症状缓解)基线WMH负荷较低(β=-0.142,95%CI -0.268至-0.016,交互作用=0.028)。失眠与WMH或淀粉样蛋白随时间积累的速率无关。在失眠参与者中,使用催眠药物与认知评分(β=0.016,95%CI -0.201至0.233,P=0.888)或发生CI(HR 0.94,95%CI 0.5-1.6,P=0.832)无关。
我们发现失眠、认知衰退和CI风险增加之间存在关联。睡眠减少的失眠与基线时较差的认知表现和较差的脑健康(WMH和淀粉样蛋白负荷)相关。睡眠时间比平时多与较低的WMH负荷相关。